SCHEMBL918429

SCHEMBL918429

CC(O)CNCCCS(=O)(=O)O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
APP P05067 1/20 0.37
PKM P14618 1/20 0.36
CA2 P00918 1/20 0.36
KDM4E B2RXH2 7/20 0.35
TDP1 Q9NUW8 3/20 0.35
LMNA P02545 2/20 0.35
GRIA1 P42261 3/20 0.33
ALDH1A1 P00352 5/20 0.33
GAA P10253 1/20 0.33
EPHX2 P34913 1/20 0.33
ANPEP P15144 1/20 0.33
ERAP2 Q6P179 1/20 0.33
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918439 1.00 KMT2A (0.38) KMT2AMEN1SMN1; SMN2RAB9AAPP
SCHEMBL918428 1.00 KMT2A (0.38) KMT2AMEN1SMN1; SMN2RAB9AAPP
SCHEMBL11147726 0.88 KMT2A (0.34) KMT2AMEN1SMN1; SMN2RAB9APKM
SCHEMBL28038412 0.86 KMT2A (0.33) KMT2AMEN1SMN1; SMN2RAB9AKDM4E
SCHEMBL917453 0.86 CA2 (0.46) APPPKMCA2LMNAGRIA1
SCHEMBL7919805 0.84 CA2 (0.45) APPPKMCA2LMNAGRIA1
SCHEMBL918218 0.82 APP (0.35) APPGRIA1ALDH1A1EPHX2
SCHEMBL14861611 0.82 APP (0.40) APPPKMCA2LMNAGRIA1
SCHEMBL11246104 0.81 ALDH1A1 (0.32) KMT2AMEN1SMN1; SMN2RAB9AKDM4E
SCHEMBL917778 0.81 APP (0.34) APPPKMCA2GRIA1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281951-A1 Compositions and methods for treating amyloidosis BHI LIMITED PARTNERSHIP (CA) 2011-11-17 US claimed
EP-1276483-B1 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES BELLUS HEALTH INT LTD (CH) 2009-09-02 EP claimed
US-20090099100-A1 Compositions and methods for treating amyloidosis BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2009-04-16 US claimed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US claimed
EP-1646659-B1 METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS KIACTA S RL (CH) 2014-05-14 EP disclosed
US-20110021813-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF KONG XIANQI 2011-01-27 US disclosed
US-20080027097-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-01-31 US disclosed
US-7311893-B2 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-12-25 US disclosed
US-7253306-B2 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-07 US disclosed
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-06-30 US disclosed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US disclosed
US-4322324-A Ampho-ionic group-containing alkyd resins NIPPON PAINT CO., LTD. (JP) 1982-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021813-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF MPST, TTR, STS KMT2A 4395/4885MEN1 1137/4885SMN1; SMN2 304/4885
US-20090099100-A1 Compositions and methods for treating amyloidosis TTR, SNCA, ARSA KMT2A 652/4885MEN1 790/4885SMN1; SMN2 23/4885
US-20110281951-A1 Compositions and methods for treating amyloidosis TTR, SNCA, ARSA KMT2A 652/4885MEN1 790/4885SMN1; SMN2 23/4885
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 KMT2A 3512/4885MEN1 605/4885SMN1; SMN2 1267/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 KMT2A 3512/4885MEN1 605/4885SMN1; SMN2 1267/4885
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof MPST, TTR, STS KMT2A 4395/4885MEN1 1137/4885SMN1; SMN2 304/4885
US-20080027097-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF MPST, TTR, STS KMT2A 4395/4885MEN1 1137/4885SMN1; SMN2 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.